The Base to Base Biotech podcast is a weekly look at what's happening in the world of biotech, with interviews with biotech leaders around the world. Whether it's a new drug, cutting-edge technology, product launches, new technology, major finding announcement or clinical trial results, Base to Base Biotech keeps you informed. The podcast is hosted by former biotech editor and broadcaster, the award-winning media veteran Jim Cornall. Base to Base is an Ayr Coastal Media Ltd production.
Required Pod Score for this show. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Verified email
Booking probability
33%
Guest openness
Selective
Sign up to generate a grounded pitch for Base to Base Biotech.
Signup to Generate a PitchThe Base to Base Biotech podcast is a weekly look at what's happening in the world of biotech, with interviews with biotech leaders around the world. Whether it's a new drug, cutting-edge technology, product launches, new technology, major finding announcement or clinical trial results, Base to Base Biotech keeps you informed.
Base to Base Biotech is hosted by Jim Cornall. The show has published 80 episodes to date.
Recent episodes include "Base to Base biotech podcast 80: Targeting tumour acidity, and developing allosteric therapies" (16 October 2026, 52 minutes), "Base to Base biotech podcast 78: A new treatment for erectile dysfunction, and nanotechnology for knee osteoarthritis" (2 October 2026, 43 minutes), and "Base to Base biotech podcast 77: Transferring mammal traits to humans, and is injecting tumours a new way to kill cancer?" (25 September 2026, 54 minutes).
Base to Base Biotech publishes roughly weekly, with episodes averaging 44 minutes across 80 episodes.
Booking probability for Base to Base Biotech is 33%, and the host is rated Selective on guests. Base to Base Biotech requires a Pod Score of 81 or higher. Base to Base Biotech's contact route on record: verified email.
The strongest fits for Base to Base Biotech are Scientific Research & Development and Pharmaceuticals. Base to Base Biotech has a health audience.
Jim Cornall hosts Base to Base Biotech, a health show with 80 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
Episode #80
This week, we chat with Ryan Beal, a cancer survivor and founder and CEO of Dyve Biosciences, about tumour acidity, and Gene Mack, president and CEO of Gain Therapeutics, about developing allosteric therapies, including...
Episode #78
This week, we chat with Lucas Decuypere, CEO and president of Allegro, about treatment of knee osteoarthritis with a nanotechnology injection, and Elin Trampe, the CEO of Dicot Pharma, a company developing a new form of...
Episode #77
This week, we chat with Evan Appleton, chief scientific officer and co-founder of Intertwined, a company focused on understanding mammalian evolved protective traits, and how they can be transferred to humans. And we...
Episode #76
This week, we have conversations with Marc Hedrick, CEO of Cerenome, about a combined approach to tackling central nervous system (CNS) cancers, and Shaun Holt, CEO of Alveo Technologies, about the potential for animal...
Episode #75
Times: 03:17 Asgard Therapeutics 32:43 Waiv This week, we talk to a company in Lund, Asgard Therapeutics, and its co-founder and CEO Cristiana Pires, about in vivo direct cell reprogramming for cancer immunotherapy, and...
Episode #74
This week, our guests are Bryan McClellan, who conducted research on pancreatic cancer as a postdoctoral fellow at Dell Medical School, and William Matsui, the study's senior author and former executive vice dean for...
Episode #72
This week, we have a conversation about the Flexible Automation for Scalable Health (FLASH) programme, focused on the development of scalable cell-free DNA bioproduction capabilities. Our guests are John Schiel, program...
Episode #71
This week, we have a conversation Paweł Szczepański, CEO of JJP Biologics about specially-built antibodies to tackle autoimmune diseases and cancer. JJP Biologics JJP Biologics is a clinical-stage biotech that leverages...
Episode #70
This week, we have a conversation with Peter G. Milner, founder and director of Renexxion, about GI motility disorders. Renexxion Renexxion, Inc. is a privately held US-headquartered clinical-stage biopharmaceutical...
Episode #69
Times: 01:33 Cyllene Tx 21:37 LinusBio This week, we have conversations with LinusBio founder and Mt. Sinai environmental professor, Dr. Manish Arora, as well as with Philippe Chambon, CEO of Cyllene Therapeutics...
Episode #68
This week, we have a conversation with Kyle Cordova, founder and CEO of AquaPoro. AquaPoro AquaPoro is a deeptech company engineering systems that can harvest water from the atmosphere based in California that was spun...
Episode #67
Times: 02:58 Deep Science Ventures 22:16 4basebio This week, we have a conversation with Amy Walker, CEO of 4basebio, and Adam Tomassi-Russell, senior director, climate, at Deep Science Ventures. 4basebio 4basebio is a...
Episode #66
This week, we have a conversation with Jeff Fischer, president of Longhorn Vaccines & Diagnostics, and with Hannah Amies, founder and CEO of Luvida. Times: 03:03 Longhorn Vaccines and Diagnostics 25:03 Luvida Longhorn...
Episode #65
This week, we have a conversation with Houdini Bio CEO and co-founder Jonathan Cohen-Gold. Houdini Bio has announced its official launch, having raised approximately £1.5m in non-dilutive grant funding and capital from...
Base to Base Biotech
This week, we have a conversation with Bora Pharmaceuticals’ chief commercial officer Jean-Baptiste (JB) Agnus. Bora Pharmaceuticals Bora Pharmaceuticals is an international contract development and manufacturing...
Episode #63
This week, we have a conversation with Mark Sawicki, president and CEO of Cryoport Systems, and we chat with Nick Manusos, CEO of Kenai Therapeutics. Times: 03:22 Cryoport Systems 22:24 Kenai Therapeutics Cryoport...
Episode #62
<p>This week, we have a conversation with Revalesio president Greg Archambeau about tackling strokes, and other conditions, with a novel method.</p><p>Revalesio</p><p>While the pharmaceutical industry often focuses on...
Episode #61
<p>This week, we speak with John Friend, CEO of Kazia Therapeutics; and have a conversation with PureTech Health CEO Robert Lyne and Eric Elenko, president and co-founder of PureTech and acting CEO of Gallop...
Episode #60
<p>This week, we have a conversation with the founder, director and chief scientific advisor of Alessa Therapeutics, Pamela Munster.</p><p>Alessa Therapeutics</p><p>Alessa Therapeutics recently announced positive...
Episode #59
<p>This week, we have a conversation with DIA chief science and regulatory officer, Maria Vassileva, and Medicus Pharma CEO, Raza Bokhari.</p><p>Times:</p><p>02:53 Medicus Pharma</p><p>29:13 DIA</p><p>DIA</p><p>DIA...
Recent guests on Base to Base Biotech. Study who booked and why before you pitch.
PitchCentric classifies Base to Base Biotech under these industries. Guests from them are the closest fit, and each links to the best podcasts in that industry.
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
Questions about the free trial? See the pricing FAQ